We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
A farnesyltransferase inhibitor improves disease phenotypes in mice with a Hutchinson-Gilford progeria syndrome mutation.
- Authors
Yang, Shao H; Meta, Margarita; Qiao, Xin; Frost, David; Bauch, Joy; Coffinier, Catherine; Majumdar, Sharmila; Bergo, Martin O; Young, Stephen G; Fong, Loren G
- Abstract
Hutchinson-Gilford progeria syndrome (HGPS) is caused by the production of a truncated prelamin A, called progerin, which is farnesylated at its carboxyl terminus. Progerin is targeted to the nuclear envelope and causes misshapen nuclei. Protein farnesyltransferase inhibitors (FTI) mislocalize progerin away from the nuclear envelope and reduce the frequency of misshapen nuclei. To determine whether an FTI would ameliorate disease phenotypes in vivo, we created gene-targeted mice with an HGPS mutation (LmnaHG/+) and then examined the effect of an FTI on disease phenotypes. LmnaHG/+ mice exhibited phenotypes similar to those in human HGPS patients, including retarded growth, reduced amounts of adipose tissue, micrognathia, osteoporosis, and osteolytic lesions in bone. Osteolytic lesions in the ribs led to spontaneous bone fractures. Treatment with an FTI increased adipose tissue mass, improved body weight curves, reduced the number of rib fractures, and improved bone mineralization and bone cortical thickness. These studies suggest that FTIs could be useful for treating humans with HGPS.
- Publication
The Journal of clinical investigation, 2006, Vol 116, Issue 8, p2115
- ISSN
0021-9738
- Publication type
Journal Article
- DOI
10.1172/JCI28968